Common Contracts

●] Common Shares (Quota Value SEK 0.04 Per Share) (including [●] American Depositary Shares, each Representing Two Common Shares) Underwriting Agreement

Underwriting Agreement • June 1st, 2020 • Calliditas Therapeutics AB • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  June 1st, 2020
• Company
  Calliditas Therapeutics AB
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This letter is being delivered to you in connection with the offering by Calliditas Therapeutics AB (the “Company”) of (i) common shares, quota value SEK 0.04 per share (the “Common Shares”), and (ii) Common Shares to be delivered in the form of American Depositary Shares (“ADSs”), of the Company, and the lock-up letter dated ______, 20__ (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated [insert date], 20__, with respect to [__ Common Shares (the “Lock-Up Shares”)] [__ ADSs (the “Lock-Up ADSs”)].

Epizyme, Inc. Shares Common Stock ($0.0001 par value) Underwriting Agreement

Underwriting Agreement • February 3rd, 2014 • Epizyme, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  February 3rd, 2014
• Company
  Epizyme, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

Epizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Company Shares”), and the persons named in Schedule II hereto (the “Selling Stockholders”) propose to sell to the several Underwriters the number of shares of Common Stock set forth in Schedule II hereto (the “Selling Stockholder Shares”) (such Company Shares and Selling Stockholder Shares collectively being hereinafter called the “Underwritten Securities”). The Company and the Selling Stockholders named in Schedule II hereto also propose to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I and Schedule II, respectively, if any (the